📊 MAZE Key Takeaways
Is Maze Therapeutics, Inc. (MAZE) a Good Investment?
Maze Therapeutics is a pre-revenue clinical-stage biopharmaceutical company burning substantial cash with no revenue generation and significant operating losses. The company is consuming capital at an unsustainable rate (-$112.7M free cash flow) despite holding $189.2M in cash, which would deplete within 1.7 years at current burn rates. Fundamental financials show a development-stage company with considerable execution risk and no demonstrated path to profitability.
Maze Therapeutics has a strong balance sheet with $189.25M of cash, minimal liabilities, and no long-term debt, which provides meaningful near-term financial flexibility for a pre-revenue biotech. However, the company remains fundamentally unprofitable with no revenue, a $131.12M net loss, and more than $112M of negative free cash flow, so the core fundamental case still depends on future pipeline execution rather than operating performance.
Why Buy Maze Therapeutics, Inc. Stock? MAZE Key Strengths
- Strong liquidity position with $189.2M cash providing runway for clinical programs
- Excellent current and quick ratios (15.50x) indicating no near-term liquidity crisis
- Zero debt burden with clean capital structure and no interest coverage concerns
- Strong liquidity with a 15.50x current and quick ratio
- Debt-free capital structure with $354.97M of equity
- Large cash balance relative to liabilities supports ongoing R&D funding
MAZE Stock Risks: Maze Therapeutics, Inc. Investment Risks
- Zero revenue with no approved products or commercialization timeline disclosed
- Operating losses of $142.9M in latest period with negative free cash flow of $112.7M indicating unsustainable burn rate
- High cash burn will require significant capital raise or dramatic cost reduction within 18-24 months to avoid depletion
- Typical biotech clinical stage risk: drug candidates may fail trials, face regulatory rejection, or require years to commercialize
- Negative ROE (-36.9%) and ROA (-33.0%) reflecting capital destruction from operations
- No revenue base, so growth quality and commercialization traction are unproven
- Heavy operating and free cash flow losses imply limited cash runway without improvement or new capital
- Negative ROE and ROA reflect weak current capital efficiency
Key Metrics to Watch
- Cash runway and quarterly burn rate trends - critical indicator of survival timeline
- Clinical trial progress and regulatory milestones for lead programs - path to potential revenue
- Operating expense trends and efficiency of R&D spending relative to pipeline advancement
- Need for additional financing and potential shareholder dilution from future capital raises
- Quarterly cash burn and remaining cash runway
- Progress toward revenue generation or major collaboration/milestone income
Maze Therapeutics, Inc. (MAZE) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 15.50x current ratio provides a solid financial cushion.
MAZE Profit Margin, ROE & Profitability Analysis
MAZE vs Healthcare Sector: How Maze Therapeutics, Inc. Compares
How Maze Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Maze Therapeutics, Inc. Stock Overvalued? MAZE Valuation Analysis 2026
Based on fundamental analysis, Maze Therapeutics, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Maze Therapeutics, Inc. Balance Sheet: MAZE Debt, Cash & Liquidity
MAZE Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Maze Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $1.25 reflects profitable operations.
MAZE Revenue Growth, EPS Growth & YoY Performance
MAZE Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $2.5M | -$24.8M | $-0.66 |
| Q2 2025 | N/A | -$32.5M | $-0.77 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Maze Therapeutics, Inc. Dividends, Buybacks & Capital Allocation
MAZE SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Maze Therapeutics, Inc. (CIK: 0001842295)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_080416.xml | View → |
| Apr 2, 2026 | 4 | xslF345X06/form4-04022026_080443.xml | View → |
| Apr 1, 2026 | 4 | xslF345X06/form4-04012026_080428.xml | View → |
| Mar 31, 2026 | 4 | xslF345X06/form4-03312026_080346.xml | View → |
| Mar 25, 2026 | 10-K | maze-20251231.htm | View → |
❓ Frequently Asked Questions about MAZE
What is the AI rating for MAZE?
Maze Therapeutics, Inc. (MAZE) has a Combined AI Rating of SELL from Claude (STRONG SELL) and ChatGPT (HOLD) with 84% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are MAZE's key strengths?
Claude: Strong liquidity position with $189.2M cash providing runway for clinical programs. Excellent current and quick ratios (15.50x) indicating no near-term liquidity crisis. ChatGPT: Strong liquidity with a 15.50x current and quick ratio. Debt-free capital structure with $354.97M of equity.
What are the risks of investing in MAZE?
Claude: Zero revenue with no approved products or commercialization timeline disclosed. Operating losses of $142.9M in latest period with negative free cash flow of $112.7M indicating unsustainable burn rate. ChatGPT: No revenue base, so growth quality and commercialization traction are unproven. Heavy operating and free cash flow losses imply limited cash runway without improvement or new capital.
What is MAZE's revenue and growth?
Maze Therapeutics, Inc. reported revenue of $0.0.
Does MAZE pay dividends?
Maze Therapeutics, Inc. does not currently pay dividends.
Where can I find MAZE SEC filings?
Official SEC filings for Maze Therapeutics, Inc. (CIK: 0001842295) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MAZE's EPS?
Maze Therapeutics, Inc. has a diluted EPS of $-3.05.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MAZE a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Maze Therapeutics, Inc. has a SELL rating with 84% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MAZE stock overvalued or undervalued?
Valuation metrics for MAZE: ROE of -36.9% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MAZE stock in 2026?
Our dual AI analysis gives Maze Therapeutics, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MAZE's free cash flow?
Maze Therapeutics, Inc.'s operating cash flow is $-111.9M, with capital expenditures of $794.0K.
How does MAZE compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -36.9% (avg: 15%), current ratio 15.50 (avg: 2).